Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Calithera Biosciences stock

CALA
US13089P1012
A12AQH

Price

0.01
Today +/-
+0.00
Today %
+35.29 %
P

Calithera Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Calithera Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Calithera Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Calithera Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Calithera Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Calithera Biosciences Stock Price History

DateCalithera Biosciences Price
11/6/20240.01 undefined
11/5/20240.01 undefined
11/1/20240.01 undefined
10/31/20240.01 undefined
10/30/20240.01 undefined
10/29/20240.01 undefined
10/25/20240.01 undefined
10/23/20240.01 undefined
10/22/20240.00 undefined
10/21/20240.00 undefined
10/18/20240.00 undefined
10/17/20240.00 undefined
10/15/20240.00 undefined
10/14/20240.00 undefined
10/11/20240.00 undefined
10/10/20240.00 undefined

Calithera Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Calithera Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Calithera Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Calithera Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Calithera Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Calithera Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Calithera Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Calithera Biosciences’s growth potential.

Calithera Biosciences Revenue, EBIT and net profit per share

DateCalithera Biosciences RevenueCalithera Biosciences EBITCalithera Biosciences Net Income
2027e800.59 M undefined30.02 M undefined4.17 M undefined
2026e519.63 M undefined-25.98 M undefined-3.82 M undefined
2025e252.95 M undefined-66.63 M undefined-10.48 M undefined
2024e0 undefined-38.53 M undefined-6.56 M undefined
2023e0 undefined-35.03 M undefined-6.71 M undefined
20220 undefined-42.07 M undefined-21.29 M undefined
20219.75 M undefined-114.23 M undefined-115.09 M undefined
20200 undefined-91.39 M undefined-90.14 M undefined
20190 undefined-92.9 M undefined-89.86 M undefined
201822.25 M undefined-57.28 M undefined-54.63 M undefined
201725.96 M undefined-29.69 M undefined-27.83 M undefined
20160 undefined-38.33 M undefined-38 M undefined
20150 undefined-32.82 M undefined-32.64 M undefined
20140 undefined-21.72 M undefined-21.71 M undefined
20130 undefined-12.38 M undefined-12.38 M undefined
20120 undefined-7.98 M undefined-5.09 M undefined

Calithera Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201220132014201520162017201820192020202120222023e2024e2025e2026e2027e
000002522009000252519800
-------12.00-------105.9554.14
----------------
0000000000000000
-7-12-21-32-38-29-57-92-91-114-42-35-38-66-2530
------116.00-259.09---1,266.67----26.19-4.823.75
-5-12-21-32-38-27-54-89-90-115-21-6-6-10-34
-140.0075.0052.3818.75-28.95100.0064.811.1227.78-81.74-71.43-66.67-70.00-233.33
0.790.790.230.90.971.651.832.373.443.694.6300000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Calithera Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Calithera Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20122013201420152016201720182019202020212022
                     
2.233.810269.951.8163.8136.2157.4115.259.525.5
000001.120.51.500
00000000000
00000000000
0.10.31.92.61.82.72.1221.91.2
2.334.1103.972.553.6167.6140.3159.9118.761.426.7
0.70.60.90.90.91.81.58.36.431.8
0002022.400000
00000000000
00000000000
00000000000
10010003003007001,000700400300300
0.80.70.93.21.224.92.596.83.32.1
3.134.8104.875.754.8192.5142.8168.9125.564.728.8
                     
10.754.3000000040.722.3
9.29.3152.2156.4172.4300.9323428.5478.6499.7510.7
-17.8-30.1-51.9-84.5-122.5-150.3-196.2-286.1-376.2-491.3-512.6
000-0.10-0.3-0.10000
00000000000
2.133.5100.371.849.9150.3126.7142.4102.449.120.4
00.20.70.60.41.11.22.123.70.7
0.91.23.43.34.18.913.617.616.410.46.7
000002900000
00000000000
00000000000
0.91.44.13.94.53914.819.718.414.17.4
00000000000
00000000000
000.30.10.43.11.16.74.81.70.9
000.30.10.43.11.16.74.81.70.9
0.91.44.444.942.115.926.423.215.88.3
334.9104.775.854.8192.4142.6168.8125.664.928.7
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Calithera Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Calithera Biosciences's financial health and stability.

Assets

Calithera Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Calithera Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Calithera Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Calithera Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-7-12-21-32-38-27-54-89-90-115-39
00000000000
00000000000
001-1135-173-3-3-7
000345769513
00000000000
00000000000
-6-11-19-29-3113-64-78-84-66-43
00000-100000
000-6623-9852-108870
000-6624-9753-108980
00000000000
00000000000
54387011122149842109
54387011122149842109
-----------
00000000000
-13168-954382946-47-34
-7.04-12-19.79-30.37-31.4312.52-65.05-78.76-84.37-66.45-43.74
00000000000

Calithera Biosciences stock margins

The Calithera Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Calithera Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Calithera Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Calithera Biosciences's sales revenue. A higher gross margin percentage indicates that the Calithera Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Calithera Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Calithera Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Calithera Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Calithera Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Calithera Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Calithera Biosciences Margin History

Calithera Biosciences Gross marginCalithera Biosciences Profit marginCalithera Biosciences EBIT marginCalithera Biosciences Profit margin
2027e0 %3.75 %0.52 %
2026e0 %-5 %-0.74 %
2025e0 %-26.34 %-4.14 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %-1,171.59 %-1,180.41 %
20200 %0 %0 %
20190 %0 %0 %
20180 %-257.44 %-245.53 %
20170 %-114.37 %-107.2 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Calithera Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Calithera Biosciences earnings per share therefore indicates how much revenue Calithera Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Calithera Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Calithera Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Calithera Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Calithera Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Calithera Biosciences Revenue, EBIT and net profit per share

DateCalithera Biosciences Sales per ShareCalithera Biosciences EBIT per shareCalithera Biosciences Earnings per Share
2027e164.39 undefined0 undefined0.86 undefined
2026e106.7 undefined0 undefined-0.79 undefined
2025e51.94 undefined0 undefined-2.15 undefined
2024e0 undefined0 undefined-1.35 undefined
2023e0 undefined0 undefined-1.38 undefined
20220 undefined-9.09 undefined-4.6 undefined
20212.64 undefined-30.96 undefined-31.19 undefined
20200 undefined-26.57 undefined-26.2 undefined
20190 undefined-39.2 undefined-37.92 undefined
201812.16 undefined-31.3 undefined-29.85 undefined
201715.73 undefined-17.99 undefined-16.87 undefined
20160 undefined-39.52 undefined-39.18 undefined
20150 undefined-36.47 undefined-36.27 undefined
20140 undefined-94.43 undefined-94.39 undefined
20130 undefined-15.67 undefined-15.67 undefined
20120 undefined-10.1 undefined-6.44 undefined

Calithera Biosciences business model

Calithera Biosciences Inc is a biopharmaceutical company specializing in the development of novel drugs for the treatment of cancer and other diseases. The company was founded in 2010 in South San Francisco, California, and has since made significant progress. History Calithera was founded by a group of successful leaders in the biotech industry who brought their extensive experience and knowledge into the development of innovative therapies. The company began its operations with the aim of finding novel molecular targets and compounds that have the potential to specifically attack cancer cells. The first product developed by the company was CB-839, an inhibitor of the enzyme glutaminase. The drug has the potential to inhibit the growth of cancer cells by disrupting the metabolic process in the cancer cells. CB-839 is currently undergoing clinical trials for the treatment of various types of cancer. Business Model Calithera Biosciences aims to address unmet medical needs by developing innovative and novel approaches to cancer and other diseases. The company takes a systematic approach and utilizes advanced technologies and research findings to develop new therapies. It works closely with leading research institutions and pharmaceutical companies to identify and develop new targets and compounds. Calithera Biosciences follows a pipeline strategy, having multiple compounds in various stages of clinical development. The company focuses on developing drugs that have high efficacy and targeted effects on cancer cells. Various Divisions Calithera Biosciences focuses on the development of drugs for the treatment of cancer and other diseases. The company has focused on researching compounds that target various factors responsible for cancer growth. The main divisions of the company are: - Metabolism: Calithera Biosciences has focused on developing drugs that inhibit the metabolism of cancer cells. CB-839, the first drug developed by the company, is an inhibitor of the enzyme glutaminase, which is important for the metabolism of cancer cells. - Immunotherapy: Calithera Biosciences has also focused on developing drugs that stimulate the immune system to fight cancer cells. The company is working on the development of drugs targeting myeloid-derived suppressor cells, a type of immune cells present in tumors. Products Calithera Biosciences has several products in development that aim to specifically attack and inhibit cancer cells. The company's key products include: - CB-839: CB-839 is an inhibitor of the enzyme glutaminase, which is important for the metabolism of cancer cells. The drug is currently undergoing clinical trials for the treatment of various types of cancer. - CB-1158: CB-1158 is an inhibitor of arginase, an enzyme important for the metabolism of immune cells. The drug has the potential to inhibit the growth of cancer cells by strengthening the immune system. CB-1158 is currently undergoing clinical trials for the treatment of various types of cancer. Conclusion Calithera Biosciences is an innovative biopharmaceutical company with a strong focus on the development of novel drugs for the treatment of cancer and other diseases. The company has focused on researching compounds that have targeted effects on cancer cells and stimulate the immune system to fight cancer cells. With a variety of compounds in different stages of clinical development, it is well positioned to bring groundbreaking therapies to the market. Calithera Biosciences is one of the most popular companies on Eulerpool.com.

Calithera Biosciences SWOT Analysis

Strengths

Calithera Biosciences Inc has several strengths that contribute to its success in the industry. Firstly, the company has a strong research and development team that constantly strives to develop innovative drugs and therapies. This enables Calithera Biosciences Inc to stay competitive and meet the evolving needs of the market.

Secondly, Calithera Biosciences Inc has established strategic partnerships with renowned pharmaceutical companies, allowing them to leverage their resources and gain access to a wider customer base. This enables the company to expand its reach and enhance its revenue streams.

Lastly, Calithera Biosciences Inc has a solid financial position, with a healthy cash flow and sufficient capital to fund its operations and growth initiatives. This provides stability and allows the company to invest in promising research projects and pursue new business opportunities.

Weaknesses

Despite its strengths, Calithera Biosciences Inc also faces certain weaknesses that need to be addressed. One weakness is a limited product portfolio, which makes the company highly dependent on the success of its few products. Any setbacks or failures in these products could significantly impact the company's financial performance.

Additionally, Calithera Biosciences Inc operates in a highly regulated industry, which increases the time and cost required for regulatory approvals. This can create delays in product launches and hamper the company's ability to quickly respond to market demands.

Opportunities

Calithera Biosciences Inc has several opportunities to explore and capitalize on in the market. The increasing demand for personalized medicine and targeted therapies presents a significant opportunity for the company. By aligning its research efforts with these emerging trends, Calithera Biosciences Inc can develop and commercialize products that cater to the specific needs of patients.

Furthermore, the growing prevalence of certain diseases, such as cancer and metabolic disorders, provides a vast market for Calithera Biosciences Inc to address. By expanding its product pipeline and developing treatments for these conditions, the company can tap into new patient populations and enhance its market share.

Threats

Calithera Biosciences Inc faces various threats that could hinder its growth and market position. One major threat is intense competition from established pharmaceutical companies and emerging biotech startups. These competitors may have superior resources, technologies, or market presence, posing a challenge to Calithera Biosciences Inc's market expansion efforts.

Additionally, the unpredictable nature of the drug development process, including clinical trial outcomes, regulatory challenges, and patent expirations, poses a significant threat to the company's sustained success. Any unforeseen setbacks in the development or commercialization of its products can lead to financial losses and hinder the company's overall growth trajectory.

Calithera Biosciences Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Calithera Biosciences Revenue by Segment

Segmente2018
Collaboration Revenue31.05 M USD

Calithera Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Calithera Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

Calithera Biosciences shares outstanding

The number of shares was Calithera Biosciences in 2023 — This indicates how many shares 4.63 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Calithera Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Calithera Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Calithera Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Calithera Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Calithera Biosciences stock splits

In Calithera Biosciences's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Calithera Biosciences.

Calithera Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-1.97 -2.01  (-2.28 %)2022 Q3
6/30/2022-2.71 -1.59  (41.23 %)2022 Q2
3/31/2022-3.77 -3.6  (4.61 %)2022 Q1
12/31/2021-4.9 -4.8  (1.96 %)2021 Q4
9/30/2021-4.65 -3  (35.5 %)2021 Q3
6/30/2021-4.9 -3.8  (22.49 %)2021 Q2
3/31/2021-5.63 -5.6  (0.54 %)2021 Q1
12/31/2020-6.61 -6.4  (3.17 %)2020 Q4
9/30/2020-6.33 -6.4  (-1.04 %)2020 Q3
6/30/2020-6.83 -5.8  (15.05 %)2020 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Calithera Biosciences stock

Eulerpool World ESG Rating (EESG©)

43/ 100

🌱 Environment

48

👫 Social

33

🏛️ Governance

49

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Calithera Biosciences shareholders

%
Name
Stocks
Change
Date
0.72774 % Molineaux (Susan M)35,44104/30/2023
0.14821 % Sjogren (Eric B)7,218-2791/23/2023
0.12109 % Wong (Stephanie)5,89704/30/2023
0.06887 % Kuriakose (Emil T.)3,35404/30/2023
0.00737 % Jones (Suzy)35904/30/2023
0.00111 % Orford (Keith)5404/30/2023
0 % Group One Trading, L.P.0-6603/31/2023
0 % FinTrust Capital Advisors, LLC0-1,2019/30/2023
0 % Arcus Capital Partners, LLC0-2503/31/2023
0 % TSP Capital Management Group, LLC0-44,7503/31/2023
1
2
3
4

Calithera Biosciences Executives and Management Board

Ms. Stephanie Wong(49)
Calithera Biosciences Chief Financial Officer, Secretary
Compensation 821,324
Dr. Susan Molineaux(69)
Calithera Biosciences President, Chief Executive Officer, Co-Founder, Director (since 2010)
Compensation 817,299
Dr. Emil Kuriakose(43)
Calithera Biosciences Chief Medical Officer
Compensation 585,448
Dr. Deepa Pakianathan(58)
Calithera Biosciences Lead Independent Director
Compensation 91,805
Dr. Sunil Agarwal(53)
Calithera Biosciences Independent Director
Compensation 64,595
1
2

Calithera Biosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Pfizer Stock
Pfizer
SupplierCustomer0,350,75-0,370,25-0,74-0,82
Antengene Corp Rg Stock
Antengene Corp Rg
SupplierCustomer0,30-0,09-0,310,670,82
Incyte Stock
Incyte
SupplierCustomer0,140,53-0,02-0,480,080,74
1

Most common questions regarding Calithera Biosciences

What values and corporate philosophy does Calithera Biosciences represent?

Calithera Biosciences Inc represents a commitment to developing cutting-edge therapies in oncology and immuno-oncology. The company focuses on discovering and commercializing novel, small-molecule drugs that target tumor metabolism and the tumor microenvironment. By leveraging their scientific expertise, Calithera Biosciences aims to create innovative treatment options for cancer patients. With a dedication to scientific rigor and collaboration, they strive to improve patient outcomes and provide hope for those affected by cancer. Calithera Biosciences Inc believes in the power of science and innovation to make a meaningful impact in the fight against cancer.

In which countries and regions is Calithera Biosciences primarily present?

Calithera Biosciences Inc primarily operates in the United States.

What significant milestones has the company Calithera Biosciences achieved?

Calithera Biosciences Inc has achieved several significant milestones. The company has successfully developed a pipeline of novel cancer therapies and conducted clinical trials for various indications. It has obtained positive results in Phase I/II studies, showcasing the effectiveness and safety of its therapies. Calithera Biosciences has also secured strategic collaborations with renowned pharmaceutical companies, enabling further development and commercialization opportunities. The company's achievements demonstrate its commitment to advancing innovative treatments and addressing unmet medical needs in the field of oncology.

What is the history and background of the company Calithera Biosciences?

Calithera Biosciences Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule drugs targeting tumor metabolism and tumor immunology. Founded in 2010, Calithera has successfully emerged as a leader in the field of cancer research. The company's extensive expertise and cutting-edge research have led to the development of innovative therapies that aim to improve the lives of patients with various types of cancer. Calithera Biosciences Inc has established collaborations with renowned academic institutions and industry partners to advance their pipeline of potential breakthrough treatments. With a strong commitment to scientific excellence, Calithera Biosciences Inc continues to strive towards transforming the landscape of cancer treatment.

Who are the main competitors of Calithera Biosciences in the market?

The main competitors of Calithera Biosciences Inc in the market include companies such as Incyte Corporation, Exelixis Inc, and Blueprint Medicines Corporation. These companies also operate in the biopharmaceutical sector and focus on developing innovative therapies for the treatment of various diseases. However, Calithera Biosciences Inc sets itself apart through its unique therapeutic approaches, cutting-edge research, and strategic partnerships. By continuously advancing its pipeline and addressing unmet medical needs, Calithera Biosciences Inc aims to remain a competitive player in the biotech industry.

In which industries is Calithera Biosciences primarily active?

Calithera Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Calithera Biosciences?

Calithera Biosciences Inc operates as a clinical-stage biopharmaceutical company. The company focuses on discovering and developing small molecule drugs targeting tumor and immune cell metabolism. It aims to develop therapies to treat patients with cancer by targeting the metabolic requirements of specific tumor and immune cell subsets. Calithera Biosciences Inc is committed to advancing its programs and exploring new therapeutic areas that have the potential to improve outcomes for patients.

What is the P/E ratio of Calithera Biosciences 2024?

The Calithera Biosciences P/E ratio is -0.01.

What is the P/S ratio of Calithera Biosciences 2024?

The Calithera Biosciences P/S ratio is 0.

What is the Quality Investing of Calithera Biosciences?

The Quality Investing for Calithera Biosciences is 3/10.

What is the revenue of Calithera Biosciences 2024?

The revenue cannot currently be calculated for Calithera Biosciences.

How high is the profit of Calithera Biosciences 2024?

The expected Calithera Biosciences profit is -6.56 M USD.

What is the business model of Calithera Biosciences

Calithera Biosciences Inc is an emerging biopharmaceutical company specializing in the development of novel cancer therapies. The company's business model consists of three core areas: research and development, clinical trials, and marketing. In research and development, Calithera Biosciences focuses on identifying and developing therapies based on enzymes and metabolic processes. These approaches aim to disrupt cancer metabolism and thereby hinder or stop tumor growth. The company has several innovative products in the pipeline developed in this way. In the field of clinical trials, Calithera Biosciences collaborates closely with doctors and researchers at universities and hospitals. The company conducts clinical trials to demonstrate the effectiveness and safety of its therapies and to obtain the necessary regulatory approvals. This phase evaluates the potential of the products and, if necessary, improves them before they are later released for marketing. The marketing and sales of Calithera Biosciences' products are carried out through its sales and marketing division. The company has previously formed partnerships with major pharmaceutical and biotech companies to distribute and market its products. However, Calithera Biosciences also retains the possibility of successfully establishing its products in the market itself. One of the company's main products is CB-839, a selective inhibitor of glutamine metabolism used in cancer treatment. This product is currently in various stages of development and is being tested in clinical trials. It is characterized by high effectiveness and tolerability. Calithera Biosciences also plays an important role in preclinical research. The company continuously investigates new therapeutic approaches and identifies promising drug candidates that can be utilized by other individuals and companies through licensing agreements. In the past, the company has licensed its technology to other companies to increase its income. The company is also financially well-positioned and has sufficient resources to further develop its pipeline - the collection of drugs under development. It has successfully raised investments from venture capital investors as well as private and institutional investors in the past. Overall, Calithera Biosciences Inc has a promising business model focused on the development of novel cancer therapies. Its innovative research, close collaboration with other institutions, and excellent financing make the company an important player in the biopharmaceutical industry.

What is the Calithera Biosciences dividend?

Calithera Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Calithera Biosciences pay dividends?

The dividend cannot currently be calculated for Calithera Biosciences or the company does not pay out a dividend.

What is the Calithera Biosciences ISIN?

The ISIN of Calithera Biosciences is US13089P1012.

What is the Calithera Biosciences WKN?

The WKN of Calithera Biosciences is A12AQH.

What is the Calithera Biosciences ticker?

The ticker of Calithera Biosciences is CALA.

How much dividend does Calithera Biosciences pay?

Over the past 12 months, Calithera Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calithera Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Calithera Biosciences?

The current dividend yield of Calithera Biosciences is .

When does Calithera Biosciences pay dividends?

Calithera Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calithera Biosciences?

Calithera Biosciences paid dividends every year for the past 0 years.

What is the dividend of Calithera Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calithera Biosciences located?

Calithera Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calithera Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calithera Biosciences from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Calithera Biosciences pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Calithera Biosciences in the year 2023?

In the year 2023, Calithera Biosciences distributed 0 USD as dividends.

In which currency does Calithera Biosciences pay out the dividend?

The dividends of Calithera Biosciences are distributed in USD.

All fundamentals about Calithera Biosciences

Our stock analysis for Calithera Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calithera Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.